Proteomics discovery of chemoresistant biomarkers for ovarian cancer therapy. (2nd October 2016)

• Record Type: Journal Article
• Authors: Deng, Junli; Wang, Li; Ni, Jie; Beretov, Julia; Wasinger, Valerie; Wu, Duojia; Duan, Wei; Graham, Peter; Li, Yong
• Is Part Of: Expert review of proteomics. Volume 13:Number 10(2016)
• Page Start: 905
• Page End: 915
• Publication Date: 2016-10-02
• Subjects: Mass spectrometry -- ovarian cancer -- proteomics -- chemoresistance -- biomarker; Proteins -- Biotechnology -- Periodicals; Proteomics -- Periodicals; 572.6
• DOI: 10.1080/14789450.2016.1233065
• Languages: English
• ISSNs: 1478-9450

Abstract

ABSTRACT: Introduction: Chemoresistance is a major challenge to current ovarian cancer chemotherapy. It is important to identify biomarkers to distinguish chemosensitive and chemoresistant patients. Areas covered: We review the medical literature, discuss MS-based technologies with respect to chemoresistant ovarian cancer and summarize the promising chemoresistant biomarkers identified. In addition, the challenges and future perspectives of biomarker discovery research are explored. With the employment of mass spectrometry-based (MS-based) proteomics, biomarker discovery of ovarian cancer has made great progress in the last decade. Many potential biomarkers were identified by MS-based proteomics technologies, some of which have been validated for further extensive studies in clinical settings. Expert commentary: The discovery of chemoresistant biomarkers is a newly developing area and may provide a clue for predicting chemotherapeutic response and discover therapeutic targets for paving the way of personalized medicine. Multiple complementary MS-based proteomics approaches hold promise for finding novel therapeutic targets in ovarian cancer treatment.